IP Library Granted Patent US 7,112,666
Granted Patent B2
US 7,112,666 · App. 10/475,538 · Granted Sep 26, 2006

Von Willebrand Factor (Vwf)-cleaving protease

Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,112,666
App. No.
10/475,538
Granted
Sep 26, 2006
Kind
B2
Abstract

This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val, and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.

Claims (5)

1. An isolated DNA comprising the nucleotide sequence as shown in SEQ ID NO: 15.

2. A vector comprising an isolated DNA comprising the nucleotide sequence as shown in SEQ ID NO: 15.

3. The vector according to claim 2 , further comprising an expression regulating sequence specialized in the expression of the polypeptide encoded by SEQ ID No: 15.

4. A cell transformed or transfected with the vector according to claim 2 .

5. A cultured host cell transformed or transfected with the expression vector according to claim 3 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 049320/0137 →
CHANGE OF NAME Recorded May 30, 2019
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 049320/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2003
From: SOEJIMA, KENJI; MIMURA, NORIKO; MAEDA, HIROAKI; NOZAKI, CHIKATERU; HAMAMOTO, TAKAYOSHI; NAKAGAKI, TOMOHIRO
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 015154/0796 →
Priority Claims (4)
JP 2001-128342 · Apr 25, 2001 · national
JP 2001-227510 · Jul 27, 2001 · national
JP 2001-302977 · Sep 28, 2001 · national
JP 2002-017596 · Jan 25, 2002 · national
Continuity (1)
Related Publication 20040214275A1 · Oct 28, 2004